Biomarkers of inflammation and endothelial dysfunction and risk of hypertension among Inner Mongolians in China

Journal of Hypertension

Volumn 28, Issue 1, 2010, Pages 35-40

  Zhang, Yonghong ^a   Thompson, Angela M ^a   Tong, Weijun ^a   Xu, Tan ^a   Chen, Jing ^a,b   Zhao, Li ^c   Kelly, Tanika N ^a   Chen, Chung Shiuan ^a   He, Jiang ^a,b  

^a TULANE UNIVERSITY   (United States)

^b TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c Tongliao Center for Disease Prevention and Control   (China)

Author keywords

Angiotensin II; Endothelial dysfunction; High sensitivity C reactive protein; Hypertension; Inflammation

Indexed keywords

ANGIOTENSIN II; BIOLOGICAL MARKER; C REACTIVE PROTEIN; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; INTERCELLULAR ADHESION MOLECULE 1; RENIN;

ADULT; ARTICLE; BLOOD PRESSURE MEASUREMENT; BLOOD SAMPLING; CHINA; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; ENDOTHELIAL DYSFUNCTION; FEMALE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SPHYGMOMANOMETER; SYSTOLIC BLOOD PRESSURE;

EID: 73849127300     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/HJH.0b013e3283324650     Document Type: Article

References (34)

1. Kearney PM, Whelton M, Reynolds K, Muntner P, Whelton PK, He J. Global burden of hypertension: analysis of worldwide data. Lancet 2005; 365:217-223.
2. He J, Gu D, Wu X, Reynolds K, Duan X, Yao C, et al. Major causes of death among men and women in China. N Engl J Med 2005; 353:1124-1134.
3. Zhang C. The role of inflammatory cytokines in endothelial dysfunction. Basic Res Cardiol 2008; 103:398-406.
4. Szmitko PE, Wang CH, Weisel RD, de Almeida JR, Anderson TJ, Verma S. New markers of inflammation and endothelial cell activation, part I. Circulation 2003; 108:1917-1923.
5. Ridker PM, Hennekens CH, Buring JE, Rifal N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 2000; 342:836-843.
6. Schillaci G, Pirro M, Gemelli F, Pasqualini L, Vaudo G, Marchesi S, et al. Increased C-reactive protein concentrations in never-treated hypertension: the role of systolic and pulse pressures. J Hypertens 2003; 21:1841-1846.
7. Bautista LE, Ló pex-Jaramillo P, Vera LM, Casas JP, Otero AP, Guaracao AI. Is C-reactive protein an independent risk factor for essential hypertension? J Hypertens 2001; 19:857-861.
8. Sung KC, Suh JY, Kim BS, Kang JH, Kim H, Lee MH, et al. High sensitivity C-reactive protein as an independent risk factor for essential hypertension. Am J Hypertens 2003; 16:429-433.
9. Lakoski SG, Herrington DM, Siscovick DM, Hulley SB. C-reactive protein concentration and incident hypertension in young adults: the CARDIA study. Arch Intern Med 2006; 166:345-349.
10. Davey Smith G, Lawlor DA, Harbord R, Rimpson N, Rumley A, Lowe GDO, et al. Association of C-reactive protein with blood pressure and hypertension life course confounding and Mendelian randomization tests of causality. Arterioscler Thromb Vasc Biol 2005; 25:1051-1056.
11. Miller MA, Kerry SM, Cook DG, Cappuccio FP. Cellular adhesion molecules and blood pressure interaction with sex in a multiethnic population. J Hypertens 2004; 22:705-711.
12. Hwang SJ, Ballantyne CM, Sharrett AR, Smith LC, Davis CE, Gotto AM, Boerwinkle E. Circulating adhesion molecules VCAM-a, ICAM-1, and E-selectin in carotid atherosclerosis and incident coronary heart disease cases. Circulation 1997; 96:4219-4225.
13. Sowers JR. Hypertension, angiotensin II and oxidative stress. N Engl J Med 2002; 346:1999-2001.
14. Dzau VJ. Tissue angiotensin and pathobiology of vascular disease: a unifying hypothesis. Hypertension 2001; 37:1047-1052.
15. Li H, Xu T, Tong W, Liu Y, Zhao L, Zhang Y. Comparison of cardiovascular risk factors between prehypertension and hypertension in a Mongolian population, inner Mongolia, China. Circ J 2008; 72:1666-1673.
16. Sun Z, Zheng L, Xu C, Li J, Zhang X, Liu S, et al. Prevalence of prehypertension, hypertension and, associated risk factors in Mongolian and Han Chinese populations in Northeast China. Int J Cardiol 2008; 128:250-254.
17. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972; 18:499-502.
18. Haber E, Koerner T, Page LB, Kliman B, Purnode A. Application of a radioimmunoassay for angiotensin I to the physiologic measurements of plasma renin activity in normal human subjects. J Clin Endocrinol Metab 1969; 29:1349-1355.
19. Fyhrquist F, Soveri P, Puutula L, Stenman U. Radioimmunoassay of plasma renin activity. Clin Chem 1976; 22:250-256.
20. Emanuel RL, Cain JP, Williams GH. Double antibody radioimmunoassay of renin activity and angiotensin II in human peripheral plasma. J Lab Clin Med 1973; 81:632-640.
21. Ridker PM. C-reactive protein and the prediction of cardiovascular events among those at intermediate risk. J Am Coll Cardiol 2007; 49:2129-2138.
22. Pasceri V, Willerson JT, Yeh ETH. Direct proinflammatory effect of C-reactive protein on human endothelial cells. Circulation 2000; 102:2165-2168.
23. DeSouza CA, Dengel DR, Macko RF, Cox K, Seals DR. Elevated levels of circulating cell adhesion molecules in uncomplicated essential hypertension. Am J Hypertens 1997; 10:1335-1341. (Pubitemid 28078736)
24. Hlubocka Z, Umnerova V, Heller S, Peleska J, Jindra A, Jachymova M, et al. Circulating intercellular cell adhesion molecule-1, endothelin-1 and von Willebrand factor-markers of endothelial dysfunction in uncomplicated essential hypertension: the effect of treatment with ACE inhibitors. J Human Hypertens 2002; 16:557-562.
25. Cottone S, Mule G, Nardi E, Vadala A, Lorito MC, Guarneri M, et al. C-reactive protein and intercellular adhesion molecule-1 are stronger predictors of oxidant stress than blood pressure in established hypertension. J Hypertens 2007; 25:423-428.
26. Schiffrin EL, Touyz RM. Multiple actions of angiotensin II in hypertension: benefits of AT1 receptor blockade. J Am Coll Cardiol 2003; 42:911-913.
27. Pastore L, Tessitore A, Martinotti S, Toniato E, Alesse E, Bravi MC, et al. Angiotensin II stimulates intercellular adhesion molecule-1 (ICAM-1) expression by human vascular endothelial cells and increases soluble ICAM-1 release in vivo. Circulation 1999; 100:1646-1652.
28. Liao TD, Yang XP, Liu YH, Shesely EG, Cavasin MA, Kuziel WA, et al. Role of inflammation in the development of renal damage and dysfunction in angiotensin II-induced hypertension. Hypertension 2008; 52:256-263.
29. He J, Klag MJ, Appel LJ, Charleston J, Whelton PK. The renin-angiotensin system and blood pressure: differences between blacks and whites. Am J Hypertens 1999; 12:555-562.
30. Alderman MH, Ooi WL, Cohen H, Madhavan S, Sealey JE, Laragh JH. Plasma renin activity: a risk factor for myocardial infarction in hypertensive patients. J Hypertens 1997; 10:1-8.
31. Bautista LE. Inflammation, endothelial dysfunction, and the risk of high blood pressure: epidemiologic and biological evidence. J Hum Hypertens 2003; 17:223-230.
32. Wang CH, Li SH, Weisel RD, Fedak PW, Dumont AS, Szmitko P, et al. C-reactive protein upregulates angiotensin type 1 receptors in vascular smooth muscle. Circulation 2003; 107:1783-1790.
33. Hingorani AD, Cross J, Kharbanda RK, Mullen MJ, Bhagat K, Taylor M, et al. Acute systemic inflammation impairs endothelium-dependent dilatation in humans. Circulation 2000; 102:994-999.
34. Panza JA, Quyyumi AA, Brush JE Jr, Epstein SE. Abnormal endothelium dependent vascular relaxation in patients with essential hypertension. N Engl J Med 1990; 323:22-27.